Overview

• The injectable combines FDA-approved PLGA with pH-sensitive Eudragit L-100 to create a biodegradable gel that releases levodopa and carbidopa steadily over seven days.
• Laboratory evaluations confirmed over 90 percent of levodopa and 81 percent of carbidopa were released with no significant toxicity in cell tests.
• A fine 22-gauge needle enables subcutaneous or intramuscular administration, eliminating the need for surgical implantation and easing dosing challenges for elderly or dysphagic patients.
• Researchers have filed an Australian patent and are seeking ethics approval to launch preclinical animal testing within six months.
• The team envisions adapting this in-situ forming platform for long-acting therapies in other chronic diseases such as diabetes and cancer.